Horan Securities, Inc. - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 173 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 0.12 and the average weighting 0.2%.

Quarter-by-quarter ownership
Horan Securities, Inc. ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$9,595
-5.6%
2660.0%0.00%
-20.0%
Q1 2023$10,159
-32.9%
2660.0%0.01%
-44.4%
Q4 2022$15,135
+37.6%
2660.0%0.01%
+28.6%
Q3 2022$11,000
-15.4%
2660.0%0.01%
-12.5%
Q2 2022$13,000
+18.2%
2660.0%0.01%
+33.3%
Q1 2022$11,0000.0%2660.0%0.01%
-14.3%
Q4 2021$11,000
-8.3%
2660.0%0.01%
-22.2%
Q2 2021$12,000
+9.1%
2660.0%0.01%0.0%
Q1 2021$11,0000.0%2660.0%0.01%0.0%
Q4 2020$11,000
+57.1%
2660.0%0.01%
+28.6%
Q3 2020$7,0000.0%2660.0%0.01%
-12.5%
Q2 2020$7,000
+40.0%
2660.0%0.01%
+14.3%
Q1 2020$5,000
+25.0%
2660.0%0.01%
+75.0%
Q3 2019$4,000
-20.0%
2660.0%0.00%
-33.3%
Q2 2019$5,000
+25.0%
2660.0%0.01%
+50.0%
Q1 2019$4,0000.0%2660.0%0.00%
-20.0%
Q4 2018$4,0000.0%2660.0%0.01%
+25.0%
Q3 2018$4,000
-20.0%
2660.0%0.00%
-20.0%
Q2 2018$5,0000.0%2660.0%0.01%
+25.0%
Q1 2018$5,0000.0%2660.0%0.00%
-20.0%
Q4 2017$5,0000.0%2660.0%0.01%0.0%
Q3 2017$5,000
+66.7%
2660.0%0.01%
+66.7%
Q2 2017$3,0000.0%2660.0%0.00%0.0%
Q1 2017$3,000
+50.0%
2660.0%0.00%0.0%
Q3 2016$2,0002660.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q2 2017
NameSharesValueWeighting ↓
SNYDER CAPITAL MANAGEMENT L P 4,324,232$165,185,6623.73%
Steamboat Capital Partners, LLC 196,898$7,521,5042.79%
2Xideas AG 600,799$22,950,5222.54%
BERNZOTT CAPITAL ADVISORS 171,808$6,563,0662.26%
Redwood Investments, LLC 328,459$12,547,1341.70%
Mesirow Institutional Investment Management, Inc. 380,415$14,531,8531.47%
Granite Investment Partners, LLC 856,253$32,708,8651.37%
Penn Capital Management Company, LLC 324,707$12,453,2111.28%
EFG Asset Management (North America) Corp. 137,739$5,262,3191.25%
First Light Asset Management, LLC 313,536$11,977,0751.14%
View complete list of HALOZYME THERAPEUTICS INC shareholders